EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

Rhea-AI Summary

Regeneron (NASDAQ: REGN) will present new clinical data for EYLEA HD (aflibercept) 8 mg at the virtual Angiogenesis meeting on February 7, 2026. Presentations include final 64-week QUASAR results in retinal vein occlusion (RVO) and full primary Phase 3b ELARA data for monthly dosing.

FDA recently approved EYLEA HD for macular edema following RVO; QUASAR met its 36-week primary endpoint and offers the first every-two-month treatment option versus prior monthly dosing. ELARA supports a monthly option for patients needing more frequent treatment. Common adverse reactions (≥3%) are listed in the safety data.

Positive

• FDA approval for EYLEA HD in macular edema following RVO (enables new labeled use)
• QUASAR met primary endpoint at 36 weeks with final results presented through 64 weeks
• First every-two-month labeled treatment option for RVO patients previously requiring monthly injections
• ELARA Phase 3b primary data support a monthly EYLEA HD option for patients needing more frequent dosing
• Presentations include a pooled safety analysis across CANDELA, PULSAR, PHOTON, and QUASAR trials

Negative

• A small subset of patients still require monthly EYLEA HD dosing despite higher dose durability
• Most common adverse reactions (≥3%) include cataract, conjunctival hemorrhage, corneal epithelium defect, increased intraocular pressure, ocular discomfort, retinal hemorrhage, blurred vision, vitreous detachment, and vitreous floaters

News Market Reaction

+1.83%

1 alert

+1.83% News Effect

On the day this news was published, REGN gained 1.83%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

QUASAR duration: 64 weeks QUASAR primary endpoint: 36 weeks ELARA dosing interval: Every 4 weeks +5 more

8 metrics

QUASAR duration 64 weeks Final long-term results in retinal vein occlusion

QUASAR primary endpoint 36 weeks Primary endpoint timing for RVO Phase 3 trial

ELARA dosing interval Every 4 weeks Phase 3b monthly dosing in wAMD or DME

EYLEA HD dose 8 mg Aflibercept injection strength

EYLEA dose 2 mg Comparator aflibercept injection strength

RVO dosing frequency Every two months EYLEA HD treatment interval option in RVO

Adverse reactions threshold ≥3% Incidence cutoff for common adverse reactions

Conference date February 7, 2026 Angiogenesis annual meeting presentations

Market Reality Check

Price: $785.51 Vol: Volume 1,171,312 vs 20-da...

normal vol

$785.51 Last Close

Volume Volume 1,171,312 vs 20-day average 922,375 (relative volume 1.27x). normal

Technical Price 741.45, trading above 200-day MA at 618.5 and 9.7% below 52-week high.

Peers on Argus

REGN fell 1.07% with peers also lower (e.g., ALNY -1.47%, ARGX -1.05%, VRTX -0.2...

REGN fell 1.07% with peers also lower (e.g., ALNY -1.47%, ARGX -1.05%, VRTX -0.27%). Scanner data does not flag a coordinated sector momentum move.

Historical Context

5 past events · Latest: Jan 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 21	Science competition support	Positive	+2.1%	Expanded funding for Regeneron Science Talent Search and student awards.
Jan 02	Earnings date notice	Neutral	-1.7%	Announcement of Q4 and full-year 2025 earnings release and call schedule.
Dec 23	Drug approval Japan	Positive	+0.8%	Dupixent approval in Japan for children 6–11 with bronchial asthma.
Dec 22	Conference presentation	Neutral	+0.8%	Planned presentation at 44th J.P. Morgan Healthcare Conference.
Dec 07	Clinical trial update	Positive	-2.1%	Encouraging Phase 1/2 Lynozyfic data in newly diagnosed multiple myeloma.

Pattern Detected

Recent news, often positive on clinical or corporate fronts, has more frequently aligned with modest price gains, though there has been at least one divergence on favorable clinical data.

Recent Company History

Over the past few months, REGN has issued a mix of corporate, clinical, and event-related updates. Philanthropic support for the Regeneron Science Talent Search on Jan 21, 2026 coincided with a +2.12% move. A Japan approval for Dupixent in pediatric asthma on Dec 23, 2025 saw shares rise 0.75%. Conference and presentation announcements around the J.P. Morgan meeting produced modest positive or neutral reactions, while encouraging Lynozyfic multiple myeloma data on Dec 7, 2025 was followed by a -2.1% decline, showing that strong clinical data has not always translated into immediate stock gains.

Market Pulse Summary

This announcement highlights new Phase 3 and Phase 3b data for EYLEA HD across retinal vein occlusio...

Analysis

This announcement highlights new Phase 3 and Phase 3b data for EYLEA HD across retinal vein occlusion, wet age-related macular degeneration, and diabetic macular edema, reinforcing its durability profile and dosing flexibility, including every-two-month and monthly regimens. Historically, REGN’s clinical and regulatory updates have produced mostly modest, aligned price moves, with occasional divergences like the -2.1% reaction to positive multiple myeloma data on Dec 7, 2025. Investors may watch detailed Angiogenesis 2026 results and subsequent regulatory or labeling developments for further context.

Key Terms

retinal vein occlusion, wet age-related macular degeneration, diabetic macular edema, anti-VEGF, +4 more

8 terms

retinal vein occlusion medical

"final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion"

Retinal vein occlusion is a blockage of one of the small veins that drain blood from the light-sensitive layer at the back of the eye, like a clogged pipe causing fluid and pressure to build up and damaging vision. For investors it matters because the condition drives demand for drugs, medical devices and procedures, influences clinical trial activity and regulatory decisions, and can materially affect revenue prospects for companies developing treatments or diagnostics.

wet age-related macular degeneration medical

"previously treated patients with wet age-related macular degeneration (wAMD) or diabetic macular edema"

A severe eye condition in which abnormal, fragile blood vessels grow beneath the macula — the small central part of the retina responsible for sharp, detailed vision — and leak fluid or blood, causing rapid loss of central sight. Investors care because the condition drives demand for high-cost therapies, medical devices and ongoing care; successful treatments can create sizable markets, affect healthcare spending and influence regulatory and reimbursement decisions, much like fixing a leaking camera lens restores image quality and value.

diabetic macular edema medical

"previously treated patients with wet age-related macular degeneration (wAMD) or diabetic macular edema"

Diabetic macular edema is an eye condition in which fluid leaks into and swells the macula, the part of the retina used for sharp, central vision, often as a complication of diabetes. For investors it matters because it drives demand for medicines, medical devices and eye-care services, influences clinical trial and regulatory outcomes, and can affect healthcare costs and revenue forecasts—think of the macula as the camera’s central lens that becomes blurred when it soaks up excess fluid.

anti-VEGF medical

"prior to which monthly treatment was required with all other anti-VEGF agents"

Anti-VEGF describes medicines or treatments that block a protein called vascular endothelial growth factor (VEGF), which tells the body to grow new blood vessels. By shutting off that signal, these therapies can slow or stop unwanted vessel growth and leaking in diseases such as certain eye disorders and cancers. Investors watch anti-VEGF programs because they can command large markets, affect patient outcomes, and drive drug sales, royalties, and valuation like controlling a major pipeline.

phase 3 technical

"final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

phase 3b technical

"a single-arm, Phase 3b trial evaluating EYLEA HD dosed every 4 weeks"

Phase 3b is an additional clinical trial stage run after the main large-scale efficacy studies but usually before or around regulatory approval; it gathers extra information on safety, dosing, specific patient groups, or real-world use to strengthen understanding of a medicine. For investors, phase 3b studies can change approval details, usage guidelines or market potential—think of them as final rehearsals that can alter the product’s launch plan and commercial prospects.

single-arm technical

"a single-arm, Phase 3b trial evaluating EYLEA HD dosed every 4 weeks"

A single-arm study is a clinical trial that gives all participants the same treatment and does not include a separate comparison group or placebo. Think of it like testing a new recipe by serving it to diners without offering a control dish — you can see how people respond, but you can’t directly compare results to another option. For investors, single-arm trials can speed development and reduce cost but leave more uncertainty about how a treatment stacks up against existing therapies and how regulators will view the evidence.

c5 inhibitor medical

"Geographic Atrophy C5 Inhibitor Trial | Glenn J. Jaffe | 11:20am"

A C5 inhibitor is a medicine that blocks a specific protein (complement component 5) in the immune system that, when overactive, can cause red blood cell destruction, clotting or inflammation. For investors, C5 inhibitors matter because they target rare but serious diseases where effective treatments can command premium pricing and steady demand; their development and approval carry high reward but also significant clinical and regulatory risk, like putting a precise brake on a malfunctioning engine.

AI-generated analysis. Not financial advice.

New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026. These include new clinical data supporting the efficacy and safety of EYLEA HD^® (aflibercept) Injection 8 mg for treating patients with serious retinal diseases.

“New presentations will further highlight the EYLEA HD clinical profile, showcasing its unparalleled durability, while allowing similar efficacy and safety to EYLEA 2 mg, but with fewer injections. This includes the Phase 3 data supporting EYLEA HD approval in RVO, where its durability offers the first every-two-month treatment option in the setting, prior to which monthly treatment was required with all other anti-VEGF agents,” said Boaz Hirshberg, M.D., Senior Vice President, Clinical Development, Internal Medicine at Regeneron. “In addition, while EYLEA HD allows for most patients to achieve longer dosing intervals, data will also be presented from the ELARA trial, supporting EYLEA HD approval as a monthly treatment for the small number of patients who need more frequent treatment. Presentations will show that patients who switched to monthly EYLEA HD from other anti-VEGF agents generally improved their vision, while also achieving better anatomic control.”

EYLEA HD was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with macular edema following retinal vein occlusion (RVO) based on data from the Phase 3 QUASAR trial, which met its primary endpoint at 36 weeks, and provides the first every-two-month treatment option for these patients who previously required more frequent treatment. At Angiogenesis, final, long-term results through the end of the trial (at 64 weeks) will be presented for the first time.

Angiogenesis will also mark the first presentation of full primary data from ELARA, a single-arm, Phase 3b trial evaluating EYLEA HD dosed every 4 weeks in previously treated patients with wet age-related macular degeneration (wAMD) or diabetic macular edema (DME). While EYLEA HD allows for most patients to achieve longer dosing intervals, with the best-in-class efficacy and safety seen with EYLEA® (aflibercept) Injection 2 mg, there are a small number of patients who still require monthly treatment even with EYLEA HD. The ELARA trial supported approval of this monthly option for some patients, while also showing that patients who switched to EYLEA HD from other anti-VEGF treatments generally improved their visual acuity while also achieving better anatomic control of retinal swelling.

The most common adverse reactions (≥3%) reported in patients treated with EYLEA HD across approved indications were cataract, conjunctival hemorrhage, corneal epithelium defect, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, retinal hemorrhage, vision blurred, vitreous detachment and vitreous floaters.

The full list of Regeneron presentations at Angiogenesis:

Presentation title	Presenter	Presentation time (EST)
Correlation of Foveal Invasion with Visual Function at Baseline in the Regeneron SIENNA Geographic Atrophy C5 Inhibitor Trial	Glenn J. Jaffe	11:20am
Safety and Efficacy of Aflibercept 8 mg in Patients With nAMD or DME: Primary Results from the Phase 3b ELARA Trial	David M. Brown	4:45pm
Aflibercept 8mg in Retinal Vein Occlusion: Final Results from the QUASAR Study*	Varun Chaudhary	4:55pm
Safety Profile of Aflibercept 8 mg: A Pooled Analysis of the CANDELA, PULSAR, PHOTON, and QUASAR Trials	John A. Wells	5:05pm

*Bayer-run trial

About EYLEA HD
Over a decade ago, Regeneron introduced EYLEA, a vascular endothelial growth factor inhibitor, and transformed the treatment paradigm for certain serious chorioretinal vascular diseases. With a well-established efficacy and consistent safety profile from 16 pivotal trials, EYLEA is approved to treat vision-threatening conditions that impact patients from their earliest days, such as retinopathy of prematurity (ROP), to their later years, including diabetic macular edema (DME), diabetic retinopathy (DR), macular edema following retinal vein occlusion (RVO) and wet age-related macular degeneration (wAMD).

Pushing the boundaries of science further to meet patient needs, EYLEA HD was developed to achieve comparable efficacy and safety to EYLEA, but with fewer injections. EYLEA HD is supported by a robust body of research and is currently approved in the U.S. to treat patients with wAMD, DME, DR and RVO.

EYLEA HD (known as Eylea™ 8 mg in the European Union and Japan) is being jointly developed by Regeneron and Bayer AG. Regeneron maintains exclusive rights to EYLEA and EYLEA HD in the U.S. Bayer has licensed the exclusive marketing rights outside of the U.S., where the companies share equally the profits from sales of EYLEA and EYLEA HD.

About Ophthalmology Development at Regeneron 
At Regeneron, we relentlessly pursue groundbreaking innovations in eye care science to help maintain the eye health of the millions of Americans impacted by vision-threatening conditions. Our expertise in angiogenesis and decades of research serve as our foundation, fueling our ongoing ambition to further innovate new solutions for patients. Our robust and diverse research and development program in ophthalmology includes efforts to potentially address additional serious eye diseases. This includes the ongoing Phase 3 SIENNA clinical trial in geographic atrophy, as well as additional novel candidates for uveitis, glaucoma and thyroid eye disease.

IMPORTANT SAFETY INFORMATION AND INDICATIONS

INDICATIONS
EYLEA HD^® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR) and Macular Edema following Retinal Vein Occlusion (RVO).

EYLEA^® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Retinopathy of Prematurity (ROP) (0.4 mg).

IMPORTANT SAFETY INFORMATION

• EYLEA HD and EYLEA are administered by injection into the eye. You should not use EYLEA HD or EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA HD or EYLEA, including aflibercept.
• Injections into the eye with EYLEA HD or EYLEA can result in an infection in the eye, retinal detachment (separation of retina from back of the eye) and, more rarely, serious inflammation of blood vessels in the retina that may include blockage. Call your doctor right away if you or your baby (if being treated with EYLEA for Retinopathy of Prematurity) experience eye pain or redness, light sensitivity, or a change in vision after an injection.
• In some patients, injections with EYLEA HD or EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
• In infants with Retinopathy of Prematurity (ROP), treatment with EYLEA will need extended periods of ROP monitoring.
• There is a potential but rare risk of serious and sometimes fatal side effects, related to blood clots, leading to heart attack or stroke in patients receiving EYLEA HD or EYLEA.
• The most common side effects reported in patients receiving EYLEA HD were cataract, increased redness in the eye, injury to the outer layer of the eye, increased pressure in the eye, eye discomfort, pain, or irritation, bleeding in the back of the eye, blurred vision, vitreous (gel-like substance) detachment, and vitreous floaters.
• The most common side effects reported in patients receiving EYLEA were increased redness in the eye, eye pain, cataract, vitreous detachment, vitreous floaters, moving spots in the field of vision, and increased pressure in the eye.
• The most common side effects reported in pre-term infants with ROP receiving EYLEA were separation of the retina from the back of the eye, increased redness in the eye, and increased pressure in the eye. Side effects that occurred in adults are considered applicable to pre-term infants with ROP, though not all were seen in clinical studies.
• You may experience temporary visual changes after an EYLEA HD or EYLEA injection and associated eye exams; do not drive or use machinery until your vision recovers sufficiently.
• These are not all the possible side effects of EYLEA HD or EYLEA. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Please click here for full Prescribing Information for EYLEA HD and EYLEA.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite^®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center^® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, such as Regeneron’s ophthalmology program as discussed or referenced in this press release (including EYLEA HD^® (aflibercept) Injection 8 mg); the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, including those referenced above; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (including the research programs discussed or referenced in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates (such as those referenced above) in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA^® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-Q for the quarterly period ended September 30, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Contacts:
Media Relations Julie Block Tel: +1 914-826-7083 julie.block@regeneron.com	Investor Relations Mark Hudson Tel: +1 914-847-3482 mark.hudson@regeneron.com

FAQ

What will Regeneron (REGN) present about EYLEA HD at Angiogenesis on February 7, 2026?

Regeneron will present final 64-week QUASAR results and full primary Phase 3b ELARA data for EYLEA HD. According to the company, presentations cover durability, efficacy compared with EYLEA 2 mg, and safety across multiple trials.

What is the significance of the QUASAR trial results for REGN's EYLEA HD (aflibercept) 8 mg?

QUASAR met its primary endpoint at 36 weeks and will show final results through 64 weeks. According to the company, this supports approval and the every-two-month dosing option for RVO patients previously treated monthly.

Does the ELARA trial change dosing options for EYLEA HD and which patients benefit, per REGN?

ELARA supports a monthly EYLEA HD dosing option for a subset of patients who need more frequent treatment. According to the company, patients switching to monthly EYLEA HD generally improved vision and anatomic control.

What safety information did Regeneron (REGN) report about EYLEA HD across trials?

Regeneron reported a pooled safety analysis and listed common adverse reactions occurring in ≥3% of patients. According to the company, these include cataract, conjunctival hemorrhage, corneal defects, increased intraocular pressure, and vitreous floaters.

How does EYLEA HD dosing differ from EYLEA 2 mg based on Regeneron (REGN) presentations?

EYLEA HD allows many patients longer dosing intervals, while maintaining similar efficacy and safety to EYLEA 2 mg. According to the company, EYLEA HD also provides a monthly option for patients who still require more frequent treatment.